Answer
Breastfeeding should be discontinued throughout treatment with Tivdak (tisotumab vedotin) and for at least 3 weeks after the last dose.
Sources for this answer
- TivdakGenmab A/S · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked